A pre-revenue biotech-to-Arctic-mining reverse-merger with world-class rocks, a speculative longevity diagnostic, and a capital structure that hardwires massive dilution.
Overview
Greenland Mines Ltd (GRML) is a newly reconstituted public company formed via a March 4, 2026 reverse merger in which legacy biotech Klotho Neurosciences acquired private Greenland Mines Corp and rebranded. The result is an unusual dual-platform conglomerate spanning Cell & Gene Therapy and Arctic Natural Resources, managed under one executive suite despite minimal operational overlap. The company is pre-revenue across both segments; near-term cash-flow hopes rest on the planned 2026 launch of the Klotho Clock (an epigenetic/AI longevity diagnostic offered B2B as Diagnostics-as-a-Service), while the therapeutic pipeline’s key asset is KLTO-202 (AAV gene therapy for ALS) still preclinical. Most implied value is tied to the Skaergaard Project in SE Greenland: a very large undeveloped Pd/Au/Pt deposit with an NI 43-101 resource and management-estimated ~$68B gross in-situ value at Feb 2026 spot prices, but with revenue highly deferred pending drilling, PEA, permitting, and multi-billion-dollar financing.